共 50 条
Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes
被引:213
|作者:
Borgia, Sergio M.
[1
]
Hedskog, Charlotte
[2
]
Parhy, Bandita
[2
]
Hyland, Robert H.
[2
]
Stamm, Luisa M.
[2
]
Brainard, Diana M.
[2
]
Subramanian, Mani G.
[2
]
McHutchison, John G.
[2
]
Mo, Hongmei
[2
]
Svarovskaia, Evguenia
[2
]
Shafran, Stephen D.
[3
]
机构:
[1] Brampton Civ Hosp, William Osler Hlth Syst, 2100 Bovaird Dr East, Brampton, ON L6R 3J7, Canada
[2] Gilead Sci, Foster City, CA USA
[3] Univ Alberta, Edmonton, AB, Canada
来源:
关键词:
genetic diversity;
genotype classification;
HCV full-genome sequencing;
GLOBAL EPIDEMIOLOGY;
SEQUENCE-ANALYSIS;
RESISTANCE;
INFECTION;
SUBTYPES;
PREVALENCE;
INHIBITOR;
PATIENT;
GENOME;
D O I:
10.1093/infdis/jiy401
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background. Hepatitis C virus (HCV) exhibits great genetic diversity and is classified into 7 genotypes (GTs), with varied geographic prevalence. Until the recent development of pangenotypic direct-acting antiviral regimens, the determination of HCV GT was necessary to inform optimal treatment. Methods. Plasma samples with unresolved GT using standard commercial genotyping methods were subjected to HCV full-genome sequencing, and phylogenetic analysis was performed to assign GT. Results. Four patients, previously classified as GT5 by LiPA or Abbott RealTime polymerase chain reaction assays, were identified as infected with a novel HCV GT. This novel HCV GT, GT8, is genetically distinct from previously identified HCV GT1-7 with > 30% nucleotide sequence divergence to the established HCV subtypes. All 4 patients were originally from Punjab, India, but now reside in Canada and are epidemiologically unlinked. Despite presence of baseline resistance-associated substitutions within the GT8 virus of all 4 patients (NS3: V36L, Q80K/R; NS5A: Q30S, Y93S), all patients achieved a sustained virologic response; 2 treated with sofosbuvir/velpatasvir/voxilaprevir for 8 weeks, 1 with sofosbuvir/ledipasvir plus ribavirin for 24 weeks and 1 with sofosbuvir plus daclatasvir for 12 weeks. Conclusions. The discovery of a novel HCV GT8 confirms the circulation of this newly identified lineage in the human population.
引用
收藏
页码:1722 / 1729
页数:8
相关论文